Prostate Cancer Diagnosis via Elemental Ratios
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for prostate cancer are invasive, inaccurate, and fail to reliably distinguish between prostate cancer and benign conditions, leading to high false-positive and false-negative results, and there is a need for a rapid and non-invasive routine test for early detection.
Innovation Solution
A method involving the determination of specific ratios and combinations of constituents such as Ca, Zn, and other elements in prostate tissue or fluid samples using Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and Inductively Coupled Atomic Emission Spectrometry (ICP-AES), which compares these ratios to control ratios to diagnose prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PSA-based multi-step diagnostic approach is used, then prostate cancer detection is performed, but specificity and sensitivity are highly inaccurate with high false-positive results
Solution Approach 1:
The patent changes the diagnostic parameters from PSA protein levels to multiple chemical element concentrations (Zn, Ca, Mg, Mn, Cu, Fe, Al, Ba, Bi, Br, Se, Cd, Co, Cr, Mo, Ni, Pb, Sr, Tl, U, Y, Zr) and their ratios. This parameter transformation enables more precise differentiation between prostate cancer and benign conditions by analyzing the unique elemental fingerprint of malignant tissue.
Solution Approach 2:
The patent employs a composite diagnostic approach by combining measurements of multiple chemical elements and their ratios rather than relying on a single marker. This composite analysis of elemental composition patterns provides superior diagnostic accuracy compared to individual markers.
2Reliability
If needle biopsy is performed, then prostate cancer diagnosis is obtained, but the procedure is invasive and painful with side effects such as prostatitis and blood in urine or semen
Solution Approach 1:
The patent replaces the mechanical invasive procedure of needle biopsy with a chemical analysis method using ICP-MS spectroscopy. This substitution eliminates physical trauma to the prostate while obtaining diagnostic information through non-invasive measurement of elemental concentrations in prostate fluid or tissue samples.
Solution Approach 2:
The patent uses chemical elements and their concentration ratios as intermediary markers that reflect the presence of prostate cancer without requiring direct tissue sampling. These elemental signatures serve as mediators that provide diagnostic information indirectly, avoiding the need for invasive mechanical intervention.
3Reliability
If digital rectal examination is performed, then prostate cancer screening is conducted, but many men find the procedure embarrassing
Solution Approach 1:
The patent replaces the embarrassing mechanical digital rectal examination with a laboratory-based chemical analysis system. This substitution transforms the diagnostic process from a personally intrusive physical examination to an objective chemical measurement, significantly improving patient acceptance while maintaining screening capability.
4Productivity
If current diagnostic methods are used, then prostate cancer screening is performed, but smaller tumors can be missed with fatal consequences because prostate tumors have the potential to suddenly grow and metastasize
Solution Approach 1:
The patent changes the detection parameters to include multiple chemical element ratios that are sensitive to early tumor changes. By monitoring changes in elemental composition patterns (particularly Zn/Ca, Zn/Mg, and other ratios), the method can detect subtle changes associated with small tumors before they become clinically apparent, preventing missed diagnoses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a rapid, specific, and sensitive diagnostic tool for prostate cancer, achieving high accuracy and specificity, allowing for early detection and differentiation from benign conditions.
Implementation Method 1
determination of specific ratios and combinations of constituents such as Ca, Zn, and other elements in prostate tissue or fluid samples using Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
Implementation Method 2
determination of specific ratios and combinations of constituents such as Ca, Zn, and other elements in prostate tissue or fluid samples using Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and Inductively Coupled Atomic Emission Spectrometry (ICP-AES)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method of diagnosing a prostate condition in a subject comprises determining, in a sample obtained from a subject, levels of a plurality of constituents selected from the group consisting of Ca, K, Mg, Zn, Ag, Al, Au, B, Ba, Bi, Br, Cd, Ce, Co, Cr, Cs, Cu, Dy, Er, Fe, Gd, Hg, Ho, La, Li, Mn, Na, Nd, Ni, P, Pb, Pr, Rb, S, Sb, Sc, Se, Si, Sm, Sr, Tb, Th, Tl, U, Y, and Zr. A combination of the levels of the plurality of constituents in the sample is compared with a combination of control levels of the same plurality of constituents. A difference between the combinations is indicative of the prostate condition.